Comparison between patients achieving a good clinical outcome (MM or better) and those still symptomatic at last follow-up
| SNMG cohort (n=82) | MM or better (n=56) | Symptomatic (n=26) | P value |
| Median age at onset (IQR), years | 36.5 (25.5–49) | 41 (26–54) | 0.4368 |
| Female | 35 (63%) | 16 (62%) | 1.000 |
| Median follow-up (IQR), months | 12 (6–18) | 9.5 (4–19) | 0.7189 |
| Clustered AChR+ | 10 (18%) | 6 (23%) | 0.565 |
| MuSK-CBA+ | 7 (12.5%) | 0 | 0.091 |
| tSNMG | 39 (70%) | 20 (77%) | 0.495 |
| Max disease severity | |||
| Ocular | 19 (34%) | 10 (39%) | 0.8048 |
| Mild | 24 (43%) | 7 (27%) | 0.2228 |
| Moderate | 10 (18%) | 9 (35%) | 0.1579 |
| Severe | 1 (2%) | 0 | 1.000 |
| Crisis | 2 (4%) | 0 | 1.000 |
| Bulbar | 19 (34%) | 5 (19%) | 0.173 |
| Immunotherapy | |||
| None | 19 (34%) | 12 (46%) | 0.3328 |
| CS | 25 (45%) | 10 (39%) | 0.6389 |
| CS+IS | 12 (21%) | 4 (15%) | 0.7653 |
| Median time from onset to therapy (IQR), months | 6.5 (1–14) | 34 (12–89) | 0.0392 |
AChR, acetylcholine receptor; CBA, cell-based assay; CS, corticosteroids; IS, immunosuppressants; MM, minimal manifestation; MuSK, muscle-specific kinase; SNMG, seronegative myasthenia gravis; tSNMG, triple seronegative myasthenia gravis.